2247614-80-6
Chemical Structure
Corubrutinib
Synonym(s): BIIB091
- CAS No.: 2247614-80-6
- Formula:C28H34N10O2
- Molecular Weight:542.64
IUPAC Name: (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide
InChIKey: JSAQBOQCZJHWMA-XMMPIXPASA-N
SMILES: O=C(C1=CN(C(C)(C)C)N=N1)N[C@H]2C3=CC=C(C4=CC=NC(NC5=CN(C)N=C5)=N4)C=C3CN(C6COC6)CC2
Biological Activity: Corubrutinib (BIIB091) is an orally active BTK inhibitor with an IC50 of <0.5 nM, Kd of 0.07 nM, and >500-fold kinome selectivity. Corubrutinib suppresses B cell activation, proliferation, differentiation, antibody production, antigen presentation, cytokine secretion, and myeloid cell effector functions. Corubrutinib exhibits favorable pharmacokinetic and preclinical safety profiles, including low genotoxic potential, minimal hepatotoxicity, and no major transporter or CYP inhibition. Corubrutinib can be used for the research of multiple sclerosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Corubrutinib | 99.85% | Corubrutinib (BIIB091) is an orally active BTK inhibitor with an IC50 of <0.5 nM, Kd of 0.07 nM, and >500-fold kinome selectivity. Corubrutinib suppresses B cell activation, proliferation, differentiation, antibody production, antigen presentation, cytokine secretion, and myeloid cell effector functions. Corubrutinib exhibits favorable pharmacokinetic and preclinical safety profiles, including low genotoxic potential, minimal hepatotoxicity, and no major transporter or CYP inhibition. Corubrutinib can be used for the research of multiple sclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bame E, et al. Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. Clinical & translational immunology. 2021;10(6):e1295. [Content Brief]
- [2]. Tsai HH, et al. First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants. Drug design, development and therapy. 2026;20:571780.
- [3]. Hopkins BT, et al. Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. Journal of medicinal chemistry. 2022 Jan 27;65(2):1206-1224. [Content Brief]
